

























































Acta Derm Venereol 2020; 100: adv00018
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta
Journal Compilation © 2020 Acta Dermato-Venereologica.
doi: 10.2340/00015555-3373
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3373
Atopic dermatitis (AD) is a common chronic, inflamma-
tory skin disorder associated with Staphylococcus aureus 
colonization and reduced microbiota diversity (1–3). New 
treatments are being evaluated using clinical AD scores 
and skin microbiota composition (4–8). Most study de-
signs include the collection of a single sample before and 
after treatment. The aim of the current evaluation was 
to analyse inter- and intra-patient variability of the skin 
microbiota of patients with AD over time to determine 
whether limited sampling is sufficient to capture the full 
extent of variability in the skin microbiota.
MATERIALS, METHODS AND RESULTS
Microbiological test results of skin swabs and clinical data from 
the placebo group of 2 phase 2 clinical trials were used in this 
evaluation (see Appendix S11 for details). Briefly, lesional and 
non-lesional skin microbiota of patients with AD were analysed 
weekly over a period of 42 days. Data from 20 patients with a 
mean ± standard deviation age of 24 ± 5 years and clinical AD score 
(objective-SCORing Atopic Dermatitis: oSCORAD) of 21.1 ± 5.6 
in the initial clinical trial (ClinicalTrials.gov: NCT03091426) were 
used to determine the variability in skin microbiota.
The coefficient of variation (CoV) represents the extent of 
variability in relation to the mean of the population. The CoV 
was calculated for microbial diversity (Shannon diversity index), 
relative abundance of Staphylococcus spp. and S. aureus concen-
tration (culture and qPCR). A CoV ≤ 25% has been considered as an 
acceptable level of variation (9, 10). To quantify the extent of inter-
patient variability of the skin microbiota, the CoV was calculated 
at each time-point for all test results. For lesional skin, high CoVs 
were observed, in the range 35.5–45.9% for microbial diversity, 
46.9–57.3% for relative abundance of Staphylococcus spp., and 
45.3–94.1% for S. aureus concentration. For microbial diversity 
of non-lesional skin, low CoVs, in the range 16.3–28.0%, were 
found. These data strongly indicate that there was considerable 
variation in lesional skin microbiota between patients.
To analyse the skin microbiota variability within an individual 
patient over time, the CoV for microbial diversity, relative abun-
dance of Staphylococcus spp. and S. aureus concentration was 
calculated per patient. For all test results of lesional skin, CoVs 
ranging between 7.1% and 173% were observed. For microbial 
diversity of non-lesional skin, low CoVs, ranging between 3.5% 
and 29.3%, were found. These data indicate that there was a wide 
range of intra-patient variability in lesional skin microbiota.
The patient population could be divided into 3 groups with 
different microbiological phenotypes, as shown by 3 represen-
tative patients in Fig. 1. The lesional skin microbiota of group I 
(orange) and II (blue) were dominated by Staphylococcus spp., 
resulting in a different profile compared with their non-lesional 
skin microbiota. These groups differed in variability, as the lesional 
skin microbiota of group II was relatively unstable (Fig. S11). The 
lesional skin microbiota of group III (red) was not dominated by 
Staphylococcus spp. Its composition and variability were similar 
to their non-lesional skin microbiota. This group had significantly 
higher microbial diversity (p < 0.001), lower relative abundance 
of Staphylococcus spp. (p < 0.001), lower S. aureus concentra-
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Fig. 1. Lesional and non-lesional skin microbiota of 3 selected patients 
representing 3 groups of patients with different microbiological 
phenotypes shown in (a, b) principal coordinates analysis (PCoA) 
plots and (c–h) bar charts. In the PCoA plots, the arrows combined with 


























































tion (p < 0.001) and lower oSCORAD (p = 0.032) compared with 
groups I and II.
Data from a separate clinical trial (ClinicalTrials.gov: 
NCT02456480) with a comparable study population, consisting 
of 12 patients with an age of 25 ± 11 years and oSCORAD of 
19.0 ± 7.4, was used for verification purposes. This second sam-
ple set confirmed the large inter- and intra-patient variability for 
lesional skin (Tables SI–SIII, Fig. S21).
DISCUSSION
To our knowledge, this is the first longitudinal analysis 
of inter- and intra-patient variability of skin microbiota 
of patients with AD. While the sampling method was 
strictly standardized, large inter- and intra-patient va-
riability for lesional skin microbiota were found. The 
large inter-patient variability originated from variable S. 
aureus abundance and environmental factors that vary 
significantly among humans (11, 12). The wide range of 
intra-patient variability indicated that the skin microbiota 
of some individuals varied more than others. Three pa-
tient groups with different microbiological phenotypes 
were defined. Groups I and II could be described as high 
Staphylococcal bioburden, low microbial diversity and 
either microbiologically stable, or unstable, respectively. 
The observation that the variability within each of these 
2 groups is consistent within subjects across longitudinal 
samples, as well as concordant in multiple microbiological 
assessments, suggests that this difference is not caused by 
variable sample quality. This difference might be caused 
by the same unidentified individual (genetic) factors 
that determine the degree of variability of healthy skin 
microbiota (13, 14). Group III was characterized by a 
significantly different lesional microbiota compared with 
groups I and II. It could be described as low Staphylococ-
cal bioburden and high microbial diversity. The relative 
lack of dysbiosis was associated with lower oSCORAD.
Because the variability over time can be high, limited 
sampling may not be sufficient to determine the effect of 
the treatment on an individual’s lesional skin microbiota. 
High sample frequency and statistical analyses methods, 
which utilize repeated measures across more than one end-
of-study time-point, may reduce the effect of the variability 
in the analyses of clinical trials. The ability to objectively 
classify subjects to the microbiological phenotypes could 
be useful in the analyses and interpretation of microbiota 
data in future clinical trials with larger sample sizes.
The limitation of the presented evaluation is that the pa-
tients administered a vehicle gel on the lesions. This could 
have had an influence on the lesional skin microbiota as it 
contains the preservative sodium benzoate. However, this 
was considered to be minimal because the concentration 
was far below the minimal inhibitory concentration for 
S. aureus. Another limitation is the small patient group 
and the omission of including patients of younger age. A 
larger and more diverse population is required to study the 
microbiological phenotype classifications and generalize 
more broadly.
In conclusion, this evaluation shows that lesional skin 
microbiota of patients with AD is characterized by large 
inter- and intra-patient variability, reflecting a highly 
individual profile. A high sample frequency, e.g. once 
weekly, yields excellent time-dependent insight into the 
changes in the variable skin microbiota, which can be 
used to determine the treatment effect on the lesional skin 
microbiota in clinical trials.
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